financetom
Business
financetom
/
Business
/
BlackLine Q2 Earnings Fall, Revenue Rises; Updates Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BlackLine Q2 Earnings Fall, Revenue Rises; Updates Guidance
Aug 5, 2025 2:46 PM

05:26 PM EDT, 08/05/2025 (MT Newswires) -- BlackLine ( BL ) reported Q2 non-GAAP earnings late Tuesday of $0.51 per diluted share, down from $0.58 a year earlier.

Analysts polled by FactSet expected $0.51.

Revenue for the quarter ended June 30 was $172.0 million, up from $160.5 million a year earlier.

Analysts surveyed by FactSet expected $170.9 million.

The company set Q3 EPS guidance of $0.48 to $0.51 on revenue of $177 million to $179 million. Analysts expected EPS of $0.56 on revenue of $177.7 million.

For the full-year 2025, it now expects adjusted EPS of $2.13 to $2.24 on revenue of $696 million to $705 million.

It previously expected adjusted EPS of $2.12 to $2.22 on revenue of $692 million to $705 million. Analysts expected $2.14 and $698.2 million, respectively.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Berkshire Hathaway not looking to buy a train company, CNBC reports
Berkshire Hathaway not looking to buy a train company, CNBC reports
Aug 25, 2025
(Reuters) -Berkshire Hathaway is not in the market to buy a train company, CEO Warren Buffett said to CNBC on Monday. The news comes weeks after reports on Berkshire-owned BNSF being in talks to acquire CSX Corp to create a transcontinental railroad. Shares of CSX fell about 4.5% after the news. Last week, CSX and BNSF announced a new coast-to-coast...
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
Aug 25, 2025
BeOne Medicines Ltd. on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. . Under the terms of the agreement, BeOne will receive an upfront payment of $885 million, with the option to sell remaining royalties within 12 months for up to $65 million....
Update: Honda Under NHTSA Probe Over Engine Failure Risk in About 1.4 Million Vehicles
Update: Honda Under NHTSA Probe Over Engine Failure Risk in About 1.4 Million Vehicles
Aug 25, 2025
01:22 PM EDT, 08/25/2025 (MT Newswires) -- (Updates with company response in the fourth paragraph.) Honda Motor ( HMC ) is facing an investigation by the US National Highway Traffic Safety Administration over complete engine failure risk in about 1.4 million of its US vehicles, the regulator disclosed Monday. The NHTSA said it received 414 reports of rod bearings failing...
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
Aug 25, 2025
BeOne Medicines Ltd. on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. . Under the terms of the agreement, BeOne will receive an upfront payment of $885 million, with the option to sell remaining royalties within 12 months for up to $65 million....
Copyright 2023-2026 - www.financetom.com All Rights Reserved